The phase 3 DREAMM 8 study (NCT04484623) compared BPd to PVd in participants with RR MM (n=302). Participants were eligible if they had received at least one prior line of therapy, including lenalidomide. The primary endpoint was PFS and Prof. Meletious Dimopoulos (University of Athens, Greece) presented the late-breaking results1.
After a median follow-up of 21.8 months, participants in the BPd arm had a significant PFS benefit over participants in the PVd arm (HR 0.52; 95% CI 0.37–0.73; P<0.001). The corresponding 12-month PFS rates were 71% and 51%, respectively. This result was consistent across subgroups, including lenalidomide-refractory and anti-CD38 therapy-refractory participants. The authors also noted a positive trend in overall survival, favouring BPd over PVd (HR 0.77; 95% CI 0.53–1.14). The 12-month overall survival rates were 83% and 76%.
“The exposure-adjusted safety profiles of the 2 treatment regimens were overall comparable,” according to Prof. Dimopoulos. Ocular events were seen in 83% of the participants on BPd. However, most of these events were manageable by dose holds and reductions in dosing frequency. In 9% of the cases, ocular events led to treatment discontinuation.
“The robust efficacy, manageable safety, and ease of administration of BPd support that this treatment regimen could become the new standard of care for patients with RR MM,” concluded Prof. Dimopoulos.
Medical writing support was provided by Robert van den Heuvel.